Diagnosing & Treating Psoriasis in Patients with Skin of Color | Pearls from the Experts
During the 2023 Skin of Color Update in New York City, esteemed experts, Dr. Andrew Alexis, Professor of Clinical Dermatology at Weill Cornell Medical College, and Dr. George Han, Associate Professor in the Department of Dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, shared their expertise in diagnosing and managing psoriasis in individuals with skin of color …
During the 2023 Skin of Color Update in New York City, esteemed experts, Dr. Andrew Alexis, Professor of Clinical Dermatology at Weill Cornell Medical College, and Dr. George Han, Associate Professor in the Department of Dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, shared their expertise in diagnosing and managing psoriasis in individuals with skin of color … 
Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium interviewed Dr. Jill S. Waibel, subsection chief of dermatology at Baptist Hospital of Miami, medical director of the Miami Cancer Institute’s Multispecialty Skin Cancer Clinic, and assistant voluntary professor at the University of Miami Miller School of Medicine. Learn about the emerging field of laser-assisted dru … 
Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium, interviewed Dr. Iltefat Hamzavi, a dermatologist with Henry Ford Health and associate professor of dermatology at Wayne State University School of Medicine. Learn from Dr. Hamzavi the key pillars of vitiligo treatment, and why there’s room to improve available options for melanocyte recruitment and repair. Dr. Hamza … 
Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium interviewed Dr. Diane S. Berson, associate professor of dermatology at Weill Cornell Medical College. Watch as Dr. Berson shares the cosmeceutical ingredients that dermatology clinicians can use synergistically to address photodamage and hyperpigmentation. Learn what ingredients are newly available and how cosmeceutica … 
Ruxolitinib (OPZELURA) is a twice daily topical cream that is FDA approved for non-segmental vitiligo and mild to moderate atopic dermatitis1. JAK inhibitors are a class of drugs effective in treating a wide variety of inflammatory conditions. Initially only FDA approved for non-dermatologic conditions such as rheumatoid arthritis and ulcerative colitis, there is now strong evidence that JAK/STAT … 